Form 8-K - Current report:
SEC Accession No. 0001193125-16-600591
Filing Date
2016-05-24
Accepted
2016-05-24 16:14:39
Documents
12
Period of Report
2016-05-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d184696d8k.htm 8-K 22975
2 EX-4.1 d184696dex41.htm EX-4.1 292297
3 EX-4.2 d184696dex42.htm EX-4.2 461176
4 EX-5.1 d184696dex51.htm EX-5.1 31869
5 GRAPHIC g184696ex51logoa.jpg GRAPHIC 2759
6 GRAPHIC g184696ex51logob.jpg GRAPHIC 2762
7 GRAPHIC g184696stp112a.jpg GRAPHIC 5986
8 GRAPHIC g184696stp112b.jpg GRAPHIC 8172
9 GRAPHIC g184696stp114.jpg GRAPHIC 7354
10 GRAPHIC g184696stp115.jpg GRAPHIC 8259
11 GRAPHIC g184696stp117a.jpg GRAPHIC 6790
12 GRAPHIC g184696stp117b.jpg GRAPHIC 10127
  Complete submission text file 0001193125-16-600591.txt   882511
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-14656 | Film No.: 161672030
SIC: 2836 Biological Products, (No Diagnostic Substances)